Literature DB >> 29600751

Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?

Andrea Rivas-Urbina1,2, Anna Rull1,3, Jordi Ordóñez-Llanos1,2, José Luis Sánchez-Quesada1,4.   

Abstract

Low-density lipoproteins (LDLs) are the major plasma carriers of cholesterol. However, LDL particles must undergo various molecular modifications to promote the development of atherosclerotic lesions. Modified LDL can be generated by different mechanisms, but as a common trait, show an increased electronegative charge of the LDL particle. A subfraction of LDL with increased electronegative charge (LDL(-)), which can be isolated from blood, exhibits several pro-atherogenic characteristics. LDL(-) is heterogeneous, due to its multiple origins but is strongly related to the development of atherosclerosis. Nevertheless, the implication of LDL(-) in a broad array of pathologic conditions is complex and in some cases anti-atherogenic LDL(-) properties have been reported. In fact, several molecular modifications generating LDL(-) have been widely studied, but it remains unknown as to whether these different mechanisms are specific or common to different pathological disorders. In this review, we attempt to address these issues examining the most recent findings on the biology of LDL(-) and discussing the relationship between this LDL subfraction and the development of different diseases with increased cardiovascular risk. Finally, the review highlights the importance of minor apolipoproteins associated with LDL(-) which would play a crucial role in the different properties displayed by these modified LDL particles. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Electronegative LDL; L5; LDL modification; apoptosis; atherosclerosis; inflammation; lipoprotein aggregation.

Mesh:

Substances:

Year:  2019        PMID: 29600751     DOI: 10.2174/0929867325666180330093953

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  5 in total

1.  Binding to heparin triggers deleterious structural and biochemical changes in human low-density lipoprotein, which are amplified in hyperglycemia.

Authors:  Shobini Jayaraman; Olivia R Chavez; Antonio Pérez; Inka Miñambres; Jose Luis Sánchez-Quesada; Olga Gursky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-04-11       Impact factor: 4.698

2.  Familial Combined Hyperlipidemia (FCH) Patients with High Triglyceride Levels Present with Worse Lipoprotein Function Than FCH Patients with Isolated Hypercholesterolemia.

Authors:  Núria Puig; Inka Miñambres; Sonia Benítez; Pedro Gil; Margarida Grau-Agramunt; Andrea Rivas-Urbina; Antonio Pérez; José Luis Sánchez-Quesada
Journal:  Biomedicines       Date:  2020-01-06

Review 3.  Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Aleksandra Stefanovic; Natasa Bogavac-Stanojevic; Ioannis Ilias; José Silva-Nunes; Anca Pantea Stoian; Andrej Janez; Manfredi Rizzo
Journal:  Pharmaceutics       Date:  2022-04-09       Impact factor: 6.525

4.  Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice.

Authors:  Andrea Rivas-Urbina; Anna Rull; Joile Aldana-Ramos; David Santos; Nuria Puig; Nuria Farre-Cabrerizo; Sonia Benitez; Antonio Perez; David de Gonzalo-Calvo; Joan Carles Escola-Gil; Josep Julve; Jordi Ordoñez-Llanos; Jose Luis Sanchez-Quesada
Journal:  Biomolecules       Date:  2020-05-29

5.  The Differential Effects of HDL Subpopulations on Lipoprotein Lipase (LPL)-Mediated VLDL Catabolism.

Authors:  Ewa Wieczorek; Agnieszka Ćwiklińska; Agnieszka Kuchta; Barbara Kortas-Stempak; Anna Gliwińska; Maciej Jankowski
Journal:  Biomedicines       Date:  2021-12-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.